Mr. Speaker, my comments were certainly not interpreted correctly. What I said is this: We intend to review the drug patent legislation, that is Bill C-91, before 1997. This is what we have been saying since the very beginning.
I mentioned, for example, the problems we are experiencing with the use of medication by certain groups, including elderly people, who often use drugs without being in possession of the necessary information. In recent years, we have noticed an increase in the number of prescriptions. This costs governments a lot of money and is a real source of concern.
As for generic products, I increased the departmental staff responsible for reviewing applications for these products, because no name drugs help us keep costs under control.